This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function.
This funding opportunity announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to develop technologies and approaches (i.e., novel ways to use new or existing technologies) that will enable researchers to study the structure and/or function of brain localized G-protein coupled receptor proteins (GPCRs) and/or potentially identify novel selective and specific agonists/antagonists to these receptor subtypes, with a focus on mental health function or dysfunction, including HIV-related neurocognitive disorders
A rich body of evidence suggests that cognitive processes are associated with particular patterns of neural activity. These data indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for cognitive improvement in neuropsychiatric disorders. This initiative encourages applications to test whether modifying electrophysiological patterns during behavior can improve cognitive abilities.
This Funding Opportunity Announcement (FOA) uses the R21 mechanism to encourage new research activities directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. The R21 activity code is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects.
The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing.
This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes.
The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. Individuals with a clinical degree who are interested in further career development in biomedical research other than patient-oriented research should refer to the Mentored Clinical Scientist Career Development (Parent K08) Award.
This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds.
The purpose of this Funding Opportunity Announcement (FOA) is to fill gaps in our understanding of a) the pathogenic interactions between HIV and hepatitis viruses, b) co-morbidities associated with HIV/hepatitis virus co-infection, and c) the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV/HCV co-infection.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD).